Sugi Predict

Sugi Predict / Compounds / SCHEMBL852835

SCHEMBL852835

SCHEMBL852835

NCCc1ccc(S(=O)(=O)Cl)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 3/20 0.67
▸ CA12 O43570 2/20 0.67
▸ CA1 P00915 2/20 0.67
▸ CA4 P22748 2/20 0.67
▸ CA6 P23280 2/20 0.67
▸ CA5A P35218 2/20 0.67
▸ CA7 P43166 2/20 0.67
▸ CA9 Q16790 2/20 0.67
▸ CA14 Q9ULX7 2/20 0.67
▸ CA5B Q9Y2D0 2/20 0.67
▸ F2 P00734 2/20 0.64
▸ TMPRSS4 Q9NRS4 2/20 0.64
▸ CYP1A2 P05177 2/20 0.64
▸ TP53 P04637 1/20 0.64
▸ CYP2D6 P10635 1/20 0.64
▸ TSHR P16473 1/20 0.64
▸ HTR6 P50406 3/20 0.60
▸ TAAR1 Q96RJ0 7/20 0.52
▸ CYP2A6 P11509 2/20 0.46
▸ LOXL2 Q9Y4K0 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluoride SCHEMBL27875099 0.98 CA12 (0.64) CA2CA12CA1CA4CA6
SCHEMBL11582128 0.86 ALDH1A1 (0.52) CA2CA12CA1CA4CA6
SCHEMBL14610271 0.85 GFER (0.58) CA2CA12CA1CA4CA6
SCHEMBL1027566 0.83 F2 (0.48) CA2CA12CA1CA4CA6
SCHEMBL27317204 0.82 CA1 (0.64) CA2CA12CA1CA4CA6
SCHEMBL6680951 0.82 HTR6 (0.84) CA2CA12CA1CA4CA6
SCHEMBL142107 0.80 CA2 (1.00) CA2CA12CA1CA4CA6
SCHEMBL27609957 0.80 ALDH1A1 (0.46) CA2CA12CA1CA4CA6
SCHEMBL3059014 0.79 RECQL (0.60) CA2CA12CA1CA4CA6
SCHEMBL1031522 0.79 F2 (0.46) CA2CA12CA1CA4CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6635802-B1 Culturing mammalian cell population in serum starvation media containing apoptosis inhibitor to increase number of cells at G0/G1 stage of cell cycle within cell population, increasing number of nuclear transfer competent cells THE TEXAS A&M UNIVERSITY SYSTEM 2003-10-21 — — US claimed
CN-111172235-B Biosensor for detecting cathepsin B and detection method and application thereof 山东师范大学 2023-03-21 — — CN disclosed
CN-111172235-A Biosensor for detecting cathepsin B and detection method and application thereof 山东师范大学 2020-05-19 — — CN disclosed
CN-108064286-A Saltant type immunoglobulin kappa chain variable region binding peptide 株式会社钟化 2018-05-22 — — CN disclosed
CN-106459953-A Method for producing recombinant proteins using recombinant brevibacillus 株式会社钟化 2017-02-22 — — CN disclosed
US-9464076-B2 Benzothiophene derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-10-11 — — US disclosed
US-20160024060-A1 BENZOTHIOPHENE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-01-28 — — US disclosed
EP-2975037-A1 BENZOTHIOPHENE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-01-20 — — EP disclosed
US-8901315-B2 Thienopyrazole derivative having PDE7 inhibitory activity DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-12-02 — — US disclosed
CN-104168908-A Romidepsin formulations and uses thereof CELGENE CORP 2014-11-26 — — CN disclosed
CN-1156476-C 1-cycloalkyl-1, 8-naphthyridin-4-one derivatives as phosphodiesterase type IV inhibitors ��һ��������ҩ��ʽ���� 2004-07-07 — — CN disclosed
US-6635802-B1 Culturing mammalian cell population in serum starvation media containing apoptosis inhibitor to increase number of cells at G0/G1 stage of cell cycle within cell population, increasing number of nuclear transfer competent cells THE TEXAS A&M UNIVERSITY SYSTEM 2003-10-21 — — US disclosed
US-6541480-B2 Controlling cytokines SUNTORY LIMITED (JP) 2003-04-01 — — US disclosed
US-20020006935-A1 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor DAIICHI ASUBIO PHARMA CO., LTD. (JP) 2002-01-17 — — US disclosed
US-6331548-B1 PREVENTION OR TREATMENT OF CYTOKINE RELATED DISEASES SUNTORY LIMITED (JP) 2001-12-18 — — US disclosed
US-6297248-B1 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor SUNTORY LIMITED (JP) 2001-10-02 — — US disclosed
CN-1256693-A 1-cycloalkyl-1,8-naphthyridin-4-one derivatives with phosphodiesterase IV inhibitory activity SUNTORY LTD (JP) 2000-06-14 — — CN disclosed
EP-0978516-A1 1-CYCLOALKYL-1,8-NAPHTHYRIDIN-4-ONE DERIVATIVES WITH PHOSPHODIESTERASE IV INHIBITORY ACTIVITY SUNTORY LIMITED (JP) 2000-02-09 — — EP disclosed
EP-0958297-A1 1-ARYL-1,8-NAPHTHYLIDIN-4-ONE DERIVATIVE AS TYPE IV PHOSPHODIESTERASE INHIBITOR SUNTORY LIMITED (JP) 1999-11-24 — — EP disclosed
WO-1999007704-A1 1-ARYL-1,8-NAPHTHYLIDIN-4-ONE DERIVATIVE AS TYPE IV PHOSPHODIESTERASE INHIBITOR SUNTORY LIMITED (JP) 1999-02-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024060-A1 BENZOTHIOPHENE DERIVATIVE PDE10A, PDE5A, PDE3B CA2 451/4885CA12 2511/4885CA1 2833/4885
US-20020006935-A1 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor PDE3A, PDE5A, PDE3B CA2 917/4885CA12 4684/4885CA1 2841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.